CMPD-1
CAS No. 41179-33-3
CMPD-1( CMPD 1 | CMPD1 )
Catalog No. M14412 CAS No. 41179-33-3
A potent, selective, non-ATP-competitive inhibitor of p38α-mediated MK2a phosphorylation with apparent Ki of 330 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 110 | In Stock |
|
| 5MG | 101 | In Stock |
|
| 10MG | 155 | In Stock |
|
| 25MG | 281 | In Stock |
|
| 50MG | 433 | In Stock |
|
| 100MG | 671 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1572 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCMPD-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, non-ATP-competitive inhibitor of p38α-mediated MK2a phosphorylation with apparent Ki of 330 nM.
-
DescriptionA potent, selective, non-ATP-competitive inhibitor of p38α-mediated MK2a phosphorylation with apparent Ki of 330 nM; dose not prevents p38α-mediated phosphorylation of MBP and ATF-2; induces a significant G2/M arrest, also inhibits tubulin polymerization in glioblastoma cells.
-
In VitroCMPD1 does not inhibit p38 MAPK-mediated phosphorylation of other two substrates, MBP and ATF2.CMPD1 induced mitotic arrest and apoptosis in U87 cells.CMPD1 inhibits tubulin polymerisation in glioblastoma cells.
-
In Vivo——
-
SynonymsCMPD 1 | CMPD1
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number41179-33-3
-
Formula Weight349.4
-
Molecular FormulaC22H20FNO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (286.20 mM)
-
SMILESO=C(NC1=CC=C(O)C=C1)CCCC2=CC=C(C3=CC=CC=C3F)C=C2
-
Chemical Name4-(2'-fluoro-[1,1'-biphenyl]-4-yl)-N-(4-hydroxyphenyl)butanamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
HS220
HS220 is an inhibitor of TAK1 which plays a key role in the signaling pathways of inflammation and cell survival.
-
CC-99677
CC-99677 (Gamcemetinib) is a selectively targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune diseases that translates biochemical potency into cellular potency as demonstrated by potent inhibition of heat shock protein 27 (HSP1) phosphorylation in LPS-activated monocyte THP-27 cells via a nucleophilic aromatic substitution (SNAr) mechanism.
-
JNJ-49095397
JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.
Cart
sales@molnova.com